Sirius XM Stock: Analysts Boost Q3 EPS Forecasts Amid Market Shifts
Barrington Research has recently elevated its Q3 2025 earnings per share (EPS) estimates for Sirius XM Holdings Inc. (NASDAQ:SIRI), signaling a notable shift in analyst sentiment regarding…
Electronic Arts (EA) Q3 EPS Estimates Soar: What Analysts Say
The financial landscape for Electronic Arts (EA) is showing robust signs of optimism, as Roth Capital recently significantly elevated its third-quarter 2026 earnings estimates for the gaming…
Algoma Steel Group’s FY2026 EPS Estimates Rise: Key Insights for Investors
Optimism is growing around Algoma Steel Group Inc.’s financial future as leading equities research firm Cormark recently lifted its earnings per share (EPS) estimates for the fiscal…
William Blair Lowers Teladoc Health EPS Estimates: Investor Impact Analyzed
Teladoc Health, a prominent virtual healthcare provider, is currently under the spotlight following a significant revision in its financial outlook. Leading equities research firm William Blair has…
Telsey Advisory Group Lowers Ethan Allen Interiors Q1 EPS Estimates
Investment analysts at Telsey Advisory Group have recently revised their first-quarter 2026 earnings per share estimates for Ethan Allen Interiors Inc. (NYSE:ETD), signaling a cautious outlook for…
UnitedHealth Group Q3 Earnings: Leerink Partners Downgrades Forecast
Leerink Partners, a prominent research firm, has issued a stark negative outlook for UnitedHealth Group’s (NYSE:UNH) Q3 2025 earnings, significantly lowering their earnings per share (EPS) estimates….
Roth Capital Cuts PURPLE INNOVATION Q3 EPS Estimates Amidst Market Shifts
Recent developments in the financial market indicate a cautious outlook for PURPLE INNOVATION, as leading research firm Roth Capital has significantly revised its earnings per share (EPS)…
William Blair Boosts Repligen’s FY2025 EPS Estimates: What Investors Need to Know
William Blair, a prominent financial analysis firm, recently revised its earnings per share (EPS) estimates for Repligen Corporation, a leading biotechnology company listed on NASDAQ under the…
William Blair Lifts Repligen’s FY2025 EPS Estimates: What Investors Need to Know
In a significant development for the biotechnology sector, leading equities research firm William Blair has revised its earnings per share (EPS) estimates for Repligen Corporation, signaling a…
Roth Capital Cuts GeoVax Labs’ FY2028 EPS Amidst Mixed Analyst Outlook
The financial landscape for GeoVax Labs Inc. recently saw a notable shift as equities research analysts at Roth Capital adjusted their future earnings projections for the biotech…